Life After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis

Overview

Journal J Blood Med

Publisher Dove Medical Press

Specialty Hematology

Date 2021 Nov 17

PMID 34785969

Citations 4

Authors

Daniela A Moraes

Maria Carolina Oliveira

Affiliations

Soon will be listed here.

Abstract

Stem cell transplantation has been investigated as treatment for severe and progressive systemic sclerosis (SSc) for the past 25 years. To date, more than 1000 SSc patients have been transplanted worldwide. Overall and event-free survival have increased over the years, reflecting stricter patient selection criteria and better clinical management strategies. This review addresses long-term outcomes of transplanted SSc patients, considering phase I/II and randomized clinical trials, as well as observational studies and those assessing specific aspects of the disease. Clinical outcomes are discussed comparatively between studies, highlighting advances, drawbacks and controversies in the field. Areas for future development are also discussed.

Citing Articles

Case report: A successful second autologous hematopoietic stem cell transplantation in refractory systemic sclerosis, with positive effect on skin involvement, pulmonary function and microcirculation.

Haverkort D, Kersten B, van Rhenen A, van der Velden W, Vonk M Front Immunol. 2022; 13:925776.

PMID: 36505455 PMC: 9727152. DOI: 10.3389/fimmu.2022.925776.

Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis.

Grasshoff H, Fourlakis K, Comduhr S, Riemekasten G Biomedicines. 2022; 10(9).

PMID: 36140251 PMC: 9496142. DOI: 10.3390/biomedicines10092150.

Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.

Ringden O, Moll G, Gustafsson B, Sadeghi B Front Immunol. 2022; 13:839844.

PMID: 35371003 PMC: 8973075. DOI: 10.3389/fimmu.2022.839844.

Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease.

Bagnato G, Versace A, La Rosa D, De Gaetano A, Imbalzano E, Chiappalone M Cells. 2022; 11(5).

PMID: 35269465 PMC: 8909673. DOI: 10.3390/cells11050843.

References

McMahan Z, Volkmann E . An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother. 2020; 21(16):2041-2056. PMC: 7913471. DOI: 10.1080/14656566.2020.1793960. View

Henes J, Koetter I, Horger M, Schmalzing M, Mueller K, Eick C . Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology (Oxford). 2014; 53(5):919-22. DOI: 10.1093/rheumatology/ket464. View

Burt R, Farge D . Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer?. Nat Rev Rheumatol. 2018; 14(4):189-191. DOI: 10.1038/nrrheum.2018.34. View

Farge D, Labopin M, Tyndall A, Fassas A, Mancardi G, van Laar J . Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2009; 95(2):284-92. PMC: 2817032. DOI: 10.3324/haematol.2009.013458. View

Snowden J, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R . Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2011; 47(6):770-90. PMC: 3371413. DOI: 10.1038/bmt.2011.185. View

Puyade M, Maltez N, Lansiaux P, Pugnet G, Roblot P, Colmegna I . Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review. Rheumatology (Oxford). 2019; 59(4):779-789. DOI: 10.1093/rheumatology/kez300. View

Snarski E, Snowden J, Oliveira M, Simoes B, Badoglio M, Carlson K . Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplant. 2014; 50(2):216-20. DOI: 10.1038/bmt.2014.248. View

Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes D, Tate T . Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol. 2016; 34(7):738-45. PMC: 5179034. DOI: 10.1038/nbt.3584. View

Franks J, Martyanov V, Wang Y, Wood T, Pinckney A, Crofford L . Machine learning predicts stem cell transplant response in severe scleroderma. Ann Rheum Dis. 2020; 79(12):1608-1615. PMC: 8582621. DOI: 10.1136/annrheumdis-2020-217033. View

10.

Sullivan K, Goldmuntz E, Keyes-Elstein L, McSweeney P, Pinckney A, Welch B . Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018; 378(1):35-47. PMC: 5846574. DOI: 10.1056/nejmoa1703327. View

11.

Harward L, Mitchell K, Pieper C, Copland S, Criscione-Schreiber L, Clowse M . The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 2012; 22(1):81-6. DOI: 10.1177/0961203312468624. View

12.

Marmont A . Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol. 2004; 17(2):223-32. DOI: 10.1016/j.beha.2004.04.004. View

13.

Henes J, Oliveira M, Labopin M, Badoglio M, Scherer H, Papa N . Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 2020; 106(2):375-383. PMC: 7849556. DOI: 10.3324/haematol.2019.230128. View

14.

Tyndall A, Bannert B, Vonk M, Airo P, Cozzi F, Carreira P . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10):1809-15. DOI: 10.1136/ard.2009.114264. View

15.

Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I . Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011; 118(6):1693-8. DOI: 10.1182/blood-2011-02-336156. View

16.

Farge D, Passweg J, van Laar J, Marjanovic Z, Besenthal C, Finke J . Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004; 63(8):974-81. PMC: 1755096. DOI: 10.1136/ard.2003.011205. View

17.

Onishi A, Sugiyama D, Kumagai S, Morinobu A . Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013; 65(7):1913-21. DOI: 10.1002/art.37969. View

18.

Kohno K, Nagafuji K, Tsukamoto H, Horiuchi T, Takase K, Aoki K . Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis. 2009; 11(4):318-23. DOI: 10.1111/j.1399-3062.2009.00401.x. View

19.

Nakamura H, Odani T, Yasuda S, Noguchi A, Fujieda Y, Kato M . Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy. Mod Rheumatol. 2017; 28(5):879-884. DOI: 10.1080/14397595.2017.1416920. View

20.

van Laar J, Farge D, Sont J, Naraghi K, Marjanovic Z, Larghero J . Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014; 311(24):2490-8. DOI: 10.1001/jama.2014.6368. View